# REZENOPY (SCN-110) PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/scn-110

> The FDA approved REZENOPY (SCN-110), sponsored by Scienture Holdings, Inc. (SCNX), on April 19, 2024.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Verified answer

### Is REZENOPY (SCN-110) FDA approved?

Yes. The FDA approved REZENOPY (SCN-110), sponsored by Scienture Holdings, Inc. (SCNX), on April 19, 2024. Press release filed with the SEC (EX-99): "LLC ("Scienture"), has entered into a definitive agreement with SUMMIT BIOSCIENCES INC. (a wholly owned subsidiary of Kindeva Drug Delivery L.P. ("Kindeva")), for the exclusive U.S. rights to commercially launch REZENOPY® (naloxone HCl) Nasal Spray 10mg, an opioid antagonist that was approved by the FDA on April 19, 2024." [Calendar and source filings](https://sec-api.dev/pdufa/scn-110)

Source: Press release filed with the SEC (EX-99), accession 0001493152-25-009737, https://www.sec.gov/Archives/edgar/data/1382574/000149315225009737/ex99-1.htm (retrieved 2026-11-12). Last confirmed 2025-03-10. Cite: https://sec-api.dev/pdufa/scn-110#answer

## Key facts

| Field | Value |
| --- | --- |
| Drug | REZENOPY (SCN-110) |
| Codes | SCN-110 |
| Sponsor | Scienture Holdings, Inc. (SCNX) https://sec-api.dev/companies/scnx/catalysts |
| Indications |  |
| Modality |  |
| FDA designations | none disclosed |

## Timeline

### April 19, 2024: FDA approval

- Status: completed, approved. Date confidence: exact.
- First seen 2025-03-10, last confirmed 2025-03-10.
- Press release filed with the SEC (EX-99) (accession 0001493152-25-009737): "LLC ("Scienture"), has entered into a definitive agreement with SUMMIT BIOSCIENCES INC. (a wholly owned subsidiary of Kindeva Drug Delivery L.P. ("Kindeva")), for the exclusive U.S. rights to commercially launch REZENOPY® (naloxone HCl) Nasal Spray 10mg, an opioid antagonist that was approved by the FDA on April 19, 2024." https://www.sec.gov/Archives/edgar/data/1382574/000149315225009737/ex99-1.htm

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/scn-110.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "REZENOPY (SCN-110) PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/scn-110

```bibtex
@misc{secapidev_pdufa_scn_110_20261116,
  title        = {REZENOPY (SCN-110) PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/scn-110}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_scn_110_20261116","title":"REZENOPY (SCN-110) PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/scn-110","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
